ERBB2 and ductal breast carcinoma in situ: Dendritic cell-based vaccines that target the HER-2 protooncogene and induce strong Th1 immunity can induce complete pathological responses in up to one third of all HER-2pos ductal carcinoma in situ patients when supplied in the neoadjuvant setting [4, 7].